The U.S. Food and Drug Administration (FDA) has approved a new class of antibiotics for treating uncomplicated urinary tract ...

The FDA has approved GSK’s Blujepa for treating uncomplicated urinary tract infections (uUTIs) in adult females and ...

Understanding this will be important if we are to use Topo VI as an antibiotic target in those bacteria that have the enzyme.

The FDA has approved GSK's gepotidacin, the first oral antibiotic to offer a new mechanism of action in uncomplicated urinary ...

Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.

The FDA approved oral gepotidacin (Blujepa) for uncomplicated urinary tract infections (UTIs) in women and girls ages 12 ...

The FDA has approved GSK’s gepotidacin (Blujepa) for treating uncomplicated urinary tract infections (uUTIs) in females aged ...

Finally, our studies of Spo11 have also provided an entry point to research on the DSBs made by the enzyme Topoisomerase II when it is inhibited by chemotherapeutic agents such as etoposide or ...

Levofloxacin 25mg/mL; contains benzyl alcohol. Levofloxacin inhibits bacterial topoisomerase IV and DNA gyrase (both of which are type II topoisomerases), enzymes required for DNA replication ...

Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes. Study participants were ...

It works by blocking bacterial DNA replication through a unique binding site, offering a new approach to tackling pathogens and offering balanced blocking of Type II topoisomerase enzymes.